Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Public health

Updated TB guidelines raise upper age limit for treating latent disease

The upper age limit for treating adults with latent tuberculosis (TB) has been increased from 35 years to 65 years in updated guidelines released by NICE. In the image, micrograph of Mycobacterium tuberculosis bacteria

Source: CDC

NICE’s updated TB guidelines are described as a “proactive” approach to the disease, which is caused by Mycobacterium tuberculosis (pictured)

The upper age limit for treating adults with latent tuberculosis (TB) has been increased from 35 years to 65 years in updated guidelines[1] released by the National Institute for Health and Care Excellence (NICE) on 13 January 2015.

The guidelines say that targeting this group of patients should increase adherence and reduce the risk of TB developing resistance to treatment. The move should also cut the overall TB drugs bill because focusing on patients who do not show symptoms and are not infectious means the disease would be stopped before it can spread.

A course of medication for latent TB is shorter, easier to stick to and cheaper than the treatment required should the disease become active and infectious, says NICE.

NICE experts describe the new guidelines as a “proactive” approach to the disease.

The guidance has a strong focus on education and says TB teams should ensure that people follow treatment plans and do not stop treatment early. This includes ensuring that people know that treatment for TB is free for everyone irrespective of their eligibility for other NHS care.

Changes to the guidelines include the recommendation that people under 65 years with evidence of latent TB and contact with an infected person can be offered six months of isoniazid (with pyridoxine) as an alternative to the existing treatment option of three months of isoniazid (with pyridoxine) and rifampicin. Choice of regimen should be based on clinical circumstances, including whether hepatotoxicity or interactions with rifamycins are a concern. Drug treatments should only be offered to adults aged between 35 years and 65 years if hepatotoxicity is not a concern.

For people with active TB, the updated guidelines state that drug regimens should be modified according to drug susceptibility testing.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200465

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now
  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £57.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The upper age limit for treating adults with latent tuberculosis (TB) has been increased from 35 years to 65 years in updated guidelines released by NICE. In the image, micrograph of Mycobacterium tuberculosis bacteria

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.